Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04175301 · ClinicalTrials.gov registry record · Phase 2
Effect H2 Water on QoL of Patients Receiving Radiotherapy for High Grade Gliomas.
A Phase 2 study of Malignant Glioma, sponsored by Stony Brook University.
- Active
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT04175301: Active Phase 2 study of Malignant Glioma, sponsored by Stony Brook University.
NCT04175301 is a Phase 2 study of Malignant Glioma that is active but no longer recruiting, run by Stony Brook University. The registered enrollment target is 15 participants, below the 92-participant average among 40 other Malignant Glioma trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04175301, a Phase 2 study of Malignant Glioma, is active but no longer recruiting, sponsored by Stony Brook University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot randomized control trial (RCT) to explore the effects of hydrogen rich water on quality of life in patients with high grade gliomas, receiving focal radiation therapy to the brain concurrent with chemotherapy with Temozolomide.
Primary Outcome
Feasibility of recruitment, assessment procedures, treatment, and outcome measures will be evaluated. Number of screened / eligible / enrolled patients, treatment adherence, assessment completion, subject dropout, data completeness, and data variability.
Conditions Studied
Interventions
- DRUG Placebo oral tablet
- DRUG Hydrogen
Study Locations (1)
New York
- Stony Brook University Medical Center - Stony Brook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-10-31 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 2 |
What the registry record for NCT04175301 still lists
NCT04175301 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 92-participant average among 40 other Malignant Glioma trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Malignant Glioma appearing as the primary indexed condition, and to 2 interventions - of which Placebo oral tablet is the first listed.
NCT04175301 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04175301 about?
NCT04175301 is a clinical study titled "Effect H2 Water on QoL of Patients Receiving Radiotherapy for High Grade Gliomas.". This is a pilot randomized control trial (RCT) to explore the effects of hydrogen rich water on quality of life in patients with high grade gliomas, receiving focal radiation therapy to the brain concurrent with chemotherapy with Temozolomide.
What is the current status of trial NCT04175301?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2019-10-31. Estimated completion is 2027-09-30.
What conditions does trial NCT04175301 study?
This clinical trial studies the following conditions: Malignant Glioma.
What interventions are being tested in trial NCT04175301?
The interventions under investigation include: Placebo oral tablet (DRUG), Hydrogen (DRUG).
Who is sponsoring clinical trial NCT04175301?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04175301 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04175301's enrollment target sits among peer trials
15 39th of 40 the lowest of 40 other Malignant Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
ACTIVE NOT RECRUITING · Phase 2
-
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
ACTIVE NOT RECRUITING · Phase 2
-
Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
ACTIVE NOT RECRUITING · Phase 2
-
Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI